RW Baird Starts Coverage of BG Medicine | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm RW Baird today initiated coverage of BG Medicine with an "Outperform" rating and a target price of $12 per share.

In a research note, analyst Quintin Lai wrote that the Waltham, Mass.-based developer of protein marker tests has demonstrated progress in its business, securing clearance with the US Food and Drug Administration in November for its Galectin-3 test for heart failure. Laboratory Corporation of America markets the test in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.